FDA Concludes Safety Review Of Novartis MS Drug Gilenya

The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple- sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug.

The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug.

Read the full story: http://hcp.lv/JZgxdd

Source: Morningstar